SuperworthAtrium Therapeutics EPS RNA
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$1.18
Atrium Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$1.18.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$1.18 | n/a | |
| Q1 FY26 | −$0.97 | n/a | |
| Q2 FY25 | −$0.75 | n/a | |
| Q1 FY25 | −$0.44 | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Atrium Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RNAAtrium Therapeutics | n/m | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Atrium Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.